Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

urities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com

INSMED I
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... July 29, 2014 The advanced optical ... brain that are driving a revolution in the neurosciences ... peer-reviewed journal published by SPIE, the international society ... coincides with the launch of the BRAIN Initiative in ... that lay out a vision for and provide examples ...
(Date:7/29/2014)... Cheshire Cat: Can a particle be separated from its ... Communications , published the results of the first Cheshire ... conducted by Chapman University in Orange, CA, and Vienna ... a cat without a grin," thought Alice in Wonderland, ... curious thing I ever saw in my life!" Alice,s ...
(Date:7/29/2014)... July 29, 2014  The Society for Clinical ... updated program for the 9 th annual ... in Amelia Island , Florida.  The focus ... remains unchanged, however, the topics and format will ... opportunity among all stakeholders with a continued focus ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3
... , AUSTIN, Texas, July 27 Patton ... of injection port therapy, announced today that they have entered into ... medical devices used in the treatment of diabetes. , , ... The two companies are working together to design and develop the ...
... SAN DIEGO, July 24 Orexigen Therapeutics, Inc. (Nasdaq: ... exercised their overallotment option to purchase an additional 1,500,000 shares ... public offering that priced on July 23, 2009. Including ... a public offering price of $7.50 per share, resulting in ...
... , , , ... , NES-ZIONA, Israel, July 24 PROLOR Biotech, Inc. (OTC Bulletin ... purchase agreements with private investors to sell up to $10 million of the ... per share. As part of the agreements, the company closed on the ...
Cached Biology Technology:Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 2Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 3Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... people in the United States have a circulatory problem ... be painful and may even require surgery in serious ... wasting and, in turn, limb amputation. , At The ... Medical School, scientists tested a non-surgical preventative treatment in ... associated with increased blood circulation. Their proof-of-concept study ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... 2010 UT Southwestern Medical Center researchers have found new ... susceptible to stress than others. In a study of ... event, animals that were more susceptible to stress exhibited enhanced ... brain. Specifically, the cells that these animals produced after a ...
... Hemophilia, a disease linked with legends of European monarchs, frail ... people today. And the very treatments that can help ... treatment is infusion with an expensively produced protein that helps ... system fights the therapy, and in a subset of those, ...
... N.J. ―The Center for Secure and Resilient Maritime Commerce (CSR) ... report. Stevens was named by the US Department ... Centers of Excellence and was selected to lead a national ... 11 universities to partner with the DHS and serve as ...
Cached Biology News:New brain nerve cells key to stress resilience, UT Southwestern researchers find 2New brain nerve cells key to stress resilience, UT Southwestern researchers find 3Researchers harness the power of plants to fight hemophilia 2Researchers harness the power of plants to fight hemophilia 3Researchers harness the power of plants to fight hemophilia 4
WIF-1 (N-20)...
... Strong reactivity with rat (100%), ... guinea pig (48%). Slight ... Specificity confirmed by Western blot ... rat Gia-1, Gia-2, rat Gia-3, ...
VEGF Receptor-2, phospho-specific (Tyr996)...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: